Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

NCT06831175 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Adrenal Cortical Carcinoma
Adrenal Cortical Cancer
Adrenal Cancer

Interventions

DRUG: Camrelizumab
DRUG: Apatinib
DRUG: mitotane

Sponsor

West China Hospital